Indikationer for nuklearmedicinske undersøgelser ved prostatacancer

Andreas Underbjerg Raade; Karen M Buch-Olsen; Lars Lund; Helle Damgaard Zacho; Michael Borre; Jorun Holm; Kasper Tholstrup Pedersen; Malene Grubbe Hildebrandt

doi:10.61409/V01240036

Indikationer for nuklearmedicinske undersøgelser ved prostatacancer

Translated title of the contribution: Indications for nuclear medicine imaging in prostate cancer

Andreas Underbjerg Raade, Karen M Buch-Olsen, Lars Lund, Helle Damgaard Zacho, Michael Borre, Jorun Holm, Kasper Tholstrup Pedersen, Malene Grubbe Hildebrandt^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

Nuclear medicine imaging for prostate cancer has advanced significantly over the past decade. A survey is presented in this review. PSMA-PET/CT is a new highly accurate method that has been introduced, but bone scans and bone-PET continue to be widely applied. PSMA-PET/CT still lacks sufficient patient outcome data to be recommended for treatment allocation when used for primary staging. However, the literature and clinical guidelines support its use at the stage of biochemical recurrence. In Denmark, the use of nuclear medicine examinations for prostate cancer aligns with clinical guideline recommendations.

Translated title of the contribution	Indications for nuclear medicine imaging in prostate cancer
Original language	Danish
Article number	V01240036
Journal	Ugeskrift for Læger
Volume	186
Issue number	23
ISSN	0041-5782
DOIs	https://doi.org/10.61409/V01240036
Publication status	Published - 25. Nov 2024

Bibliographical note

Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.

Documents & Links

10.61409/V01240036Licence: CC BY-NC-ND

Open Access VersionFinal published version, 346 KBLicence: CC BY-NC-ND

Cite this

@article{fb7e6041094d47f4bd0943b2fa4ce9ca,

title = "Indikationer for nuklearmedicinske unders{\o}gelser ved prostatacancer",

abstract = "Nuclear medicine imaging for prostate cancer has advanced significantly over the past decade. A survey is presented in this review. PSMA-PET/CT is a new highly accurate method that has been introduced, but bone scans and bone-PET continue to be widely applied. PSMA-PET/CT still lacks sufficient patient outcome data to be recommended for treatment allocation when used for primary staging. However, the literature and clinical guidelines support its use at the stage of biochemical recurrence. In Denmark, the use of nuclear medicine examinations for prostate cancer aligns with clinical guideline recommendations.",

keywords = "Humans, Male, Prostatic Neoplasms/diagnostic imaging, Positron Emission Tomography Computed Tomography, Bone Neoplasms/diagnostic imaging, Radiopharmaceuticals, Nuclear Medicine, Neoplasm Staging, Neoplasm Recurrence, Local/diagnostic imaging, Practice Guidelines as Topic",

author = "Raade, {Andreas Underbjerg} and Buch-Olsen, {Karen M} and Lars Lund and Zacho, {Helle Damgaard} and Michael Borre and Jorun Holm and Pedersen, {Kasper Tholstrup} and Hildebrandt, {Malene Grubbe}",

note = "Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.",

year = "2024",

month = nov,

day = "25",

doi = "10.61409/V01240036",

language = "Dansk",

volume = "186",

journal = "Ugeskrift for L{\ae}ger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "23",

}

TY - JOUR

T1 - Indikationer for nuklearmedicinske undersøgelser ved prostatacancer

AU - Raade, Andreas Underbjerg

AU - Buch-Olsen, Karen M

AU - Lund, Lars

AU - Zacho, Helle Damgaard

AU - Borre, Michael

AU - Holm, Jorun

AU - Pedersen, Kasper Tholstrup

AU - Hildebrandt, Malene Grubbe

N1 - Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.

PY - 2024/11/25

Y1 - 2024/11/25

N2 - Nuclear medicine imaging for prostate cancer has advanced significantly over the past decade. A survey is presented in this review. PSMA-PET/CT is a new highly accurate method that has been introduced, but bone scans and bone-PET continue to be widely applied. PSMA-PET/CT still lacks sufficient patient outcome data to be recommended for treatment allocation when used for primary staging. However, the literature and clinical guidelines support its use at the stage of biochemical recurrence. In Denmark, the use of nuclear medicine examinations for prostate cancer aligns with clinical guideline recommendations.

AB - Nuclear medicine imaging for prostate cancer has advanced significantly over the past decade. A survey is presented in this review. PSMA-PET/CT is a new highly accurate method that has been introduced, but bone scans and bone-PET continue to be widely applied. PSMA-PET/CT still lacks sufficient patient outcome data to be recommended for treatment allocation when used for primary staging. However, the literature and clinical guidelines support its use at the stage of biochemical recurrence. In Denmark, the use of nuclear medicine examinations for prostate cancer aligns with clinical guideline recommendations.

KW - Humans

KW - Male

KW - Prostatic Neoplasms/diagnostic imaging

KW - Positron Emission Tomography Computed Tomography

KW - Bone Neoplasms/diagnostic imaging

KW - Radiopharmaceuticals

KW - Nuclear Medicine

KW - Neoplasm Staging

KW - Neoplasm Recurrence, Local/diagnostic imaging

KW - Practice Guidelines as Topic

U2 - 10.61409/V01240036

DO - 10.61409/V01240036

M3 - Tidsskriftartikel

C2 - 39221880

SN - 0041-5782

VL - 186

JO - Ugeskrift for Læger

JF - Ugeskrift for Læger

IS - 23

M1 - V01240036

ER -

Indikationer for nuklearmedicinske undersøgelser ved prostatacancer

Abstract

Bibliographical note

Documents & Links

Fingerprint

Cite this